There is much talk about the ever-increasing role of patient-facing technologies in clinical trials, however, as the industry progresses in the 'early adoption stage' into 'early majority', many organizations struggle with the preparation for these new protocol components and possible extended team members.

Let's begin with what is defined and what still needs to be sorted with this new virtual ecosystem, as we are always learning. What exactly do terms like remote, site-less, hybrid, and decentralized trials mean and do for us? In order to work together, we need to better understand each other and what terms help and hinder our progress.